Bridging the gap


Intravacc develops innovative platforms and methods to improve the effectiveness, stability and safety of vaccines.

Read More Close

Intravacc is continuously investing in R&D platforms to facilitate vaccine development. Early development includes vaccine strain design to generate bacterial, viral and cellular seeds for efficient vaccine production.

We also carry out studies on adjuvants and delivery systems, resulting in safe products that are efficacious.

Our successful R&D efforts are then further developed into services we offer to clients.

To investigate the efficacy of vaccines, Intravacc performs immunological research to unravel the mechanisms of action of vaccine concepts. These immunological assays are used during preclinical and clinical stages.    


Our expertise includes

  • Immunology
  • Molecular biology
  • Animal models
  • Systems vaccinology
  • Adjuvants
  • Vaccine delivery





Want to know more? Contact us at


Process Development

Process Development

Intravacc develops bacterial and viral vaccines from discovery to phase II clinical trials. We use our own advanced technologies, such as Vero cell line and the OMV platform.

Read More Close

We can apply our long-standing and extensive experience in vaccine development to design rational and modelled processes together with our clients.

Using mathematical models we can safely scale from lab to commercial scale bioreactors.


Viral vaccine R&D

Focusing on the treatment or prevention of viral diseases such as Polio, Respiratory Syncytial Virus, Enterovirus, Influenza, Rabies and Rotavirus. We have access to a qualified Vero cell line and specialized equipment to perform research for WHO, the Dutch Ministry of Health and collaborate with other parties.


Bacterial Vaccine R&D

Focusing on Conjugate vaccine technology (for vaccines for Hib and Shigella) and Outer Membrane Vescicles (OMV) technology (Pertussis, Meningococcal B, Lyme disease and Tuberculosis research)



Main features

  • Established cGMP Vero cell line
  • Technology platform suitable for highly purified inactivated and live-attenuated vaccines
  • OMV-based vaccine technology platform suitable for heterologous antigen expression
  • State-of-the-art production technologies (including single-use and re-usable equipment)
  • Highly qualified BSL-2 and GxP trained personnel
  • Experience in Design of Experiments (DoE), and multiparametric data analysis
  • High-throughput methods for both Up-stream and Down-stream processing
  • Animal Component Free and Chemically Defined processing as standard methods
  • Tested processes to assure process robustness and reproducibility
  • Full panel of analytical capabilities for in-process controls
  • Scalable processes from 2 mL to pilot-scale and commercial manufacturing scale
  • Experience in Technology Transfer of vaccine production processes
  • CMC consulting capacities


Check out our factsheets:

Hand Foot Mouth Disease




OMV Pertussis


Sabin IPV

Vero cells


Want to know more? Contact us at:



Intravacc offers assay development and vaccine characterization services. We specialise in immunoassays, molecular biology methods, physicochemical analyses, and biological assays.

Read More Close

Assays to prove the quality of a new vaccine

The quality is a decisive factor in the development of new vaccines. Intravacc uses multiple instructive assays and innovative techniques to guarantee the quality of intermediates and finished product. Our tests focus on the composition, concentration, efficacy, purity, safety, stability and identity of the new vaccine candidate.



  • ELISA (direct and capture assays for antibody titres in sera and antigen concentrations in vaccine formulations)
  • Multiplex Immunoassay (cytokines, antibody titres against multiple antigens, antigen concentrations in combination vaccines)
  • Biosensor analysis (epitope integrity, epitope mapping, affinity measurements, calibration free concentration analysis)
  • Immunoproteomics (identification of immunogenic proteins, B-cell epitopes and naturally processed T-cell epitopes by mass spectrometry)


Molecular biology methods

  • qPCR (quantification of viruses and bacteria by real time Polymerase Chain Reaction)
  • Deep sequencing (identity, sequence and genetic changes of viruses)


Physicochemical analyses

  • Mass spectrometry (identity, quantity, purity and chemical modifications of antigens, host cell proteins)
  • 2-D electrophoresis (antigen composition )
  • Fluorescence spectroscopy (conformation and aggregation of antigens)
  • Circular dichroism (secondary and tertiary structure of antigens)
  • Differential scanning calorimetry (denaturation temperature of antigens)
  • particle analysis by Dynamic Light Scattering (DLS), Field Flow Fractionation - Multiangle Laser Light Scattering (FFF-MALLS) 


Analytical techniques

  • HPLC (amino acid determination, residual phenol, monosaccharides, oligosaccharides, excipients)
  • GC (LPS analysis, phospholipids)
  • NMR (medium composition, metabolite analysis, chemical composition, impurities, excipients)


Biological assays

  • CCID50 (active virus titre)
  • Vero cell assay (residual toxin activity)


Want to know more? Contact us at:

Animal models

Animal models

Intravacc is one of the leading players in global 3R research (reduce, replace and refine animal experiments).

Read More Close

We have developed several new methods, some of which were accepted by the European Pharmacopoeia.

In addition, we are a front runner in the development and distribution of a new paradigm in vaccine lot release testing, known as the consistency approach. To promote the implementation of this strategy, we participate in an IMI-funded European consortium on consistency testing.


Research focus:

  • Cell-based in vitro models, pysico-chemical techniques and immunochemical assays
  • Development of in-vitro assays
  • Transgenic mouse model for neurovirulence testing of OPV or Sabin-IPV lots


Achievements include:

  • Vero cell tests replacing the specific toxicity test in guinea pigs (diphtheria vaccine)
  • Serological tests replacing challenge procedures in potency testing (diphtheria and tetanus vaccine)
  • The use of human endpoints replacing lethal/severe clinical endpoints 


Check out our factsheet on our 3R research


Want to know more? Contact us at:

Pilot-scale production

Pilot-scale production

Intravacc is home to a GMP facility for production of vaccines on pilot scale. This includes a state-of-the-art 100 m2 C/BSL-2 cleanroom.

Read More Close

Intravacc has years of experience in producing GMP batches for phase I and II clinical studies of viral and bacterial vaccines.

We have all the required equipment at our disposal for Upstream and Downstream Processing, including bioreactors of up to 100 liter.

This means we can offer a complete CTM production trajectory from seed lot production till released clinical batches.



  • Fully adaptable cleanrooms
  • 100m2 class C/BSL-2 cleanroom for active processes
  • 25m2 class C cleanroom for inactive processes
  • Dedicated cleaning & sterilization department


Want to know more? Contact us at:

Clinical & Regulatory

Clinical & Regulatory

Our inhouse clinical and regulatory scientists form part of each project team that develops a new vaccine. They offer regulatory support right from the start.

Read More Close

Innovative vaccines are mostly complex products for which there is often no clear regulatory guidance available. That is why our Regulatory and Clinical Affairs (RCA) team is involved in the development of these products right from the start.

By taking into consideration the regulatory restraints and requirements in an early phase of development, a lean transition to the next phase towards a marketed product can be made. 

Our team provides regulatory support in vaccine development projects through early involvement, assessment of potential regulatory requirements, preparation of risk assessments and by seeking informal or formal scientific advice with national competent authorities.

Support varies from the preparation of pharmaceutical, preclinical, and clinical development plans and reports, to the submission of relevant regulatory dossiers (IMPD/IND, CTA) to health authorities.


CMC activities

  • Raw materials assessment
  • Quality Target Product Profile-design, define product specifications
  • Gap analyses and risk assessments (e.g. Viral safety/TSE/Impurities/GMOs)
  • Design of program for stability testing
  • Comparability studies


  • Pre-clinical evaluation of vaccine immunogenicity, efficacy
  • Coordination of non-clinical toxicology and safety studies
  • Non-clinical development plan


  • Product Profile design
  • Clinical Development Pathway advise
  • Clinical study design
  • CRO selection and management


Want to know more? Contact us at:

Co-Development with partners

Co-Development with partners

We are always open to work closely together with academia, public health organizations (WHO, BMGF), and biotech and pharmaceutical companies. This way, we benefit from each other's strengths in developing and innovating vaccines.

Read More Close

Are you looking for an experienced partner who can take your discovery to the next level of preclinical research?

Are you looking for a partner with GMP facilities, who can produce clinical lot material for your toxicity studies and phase I/II clinical trials?

Are you looking for a partner with a patent portfolio covering a variety of vaccine leads, novel vaccine technologies and adjuvants?

We are happy to discuss these and other possibilities for collaboration and co-development.


Vaccine concepts/technologies available for licensing

  • RSV
  • EV71
  • Pertussis
  • Alzheimer
  • LPS-mutants
  • Vero cells
  • MenB
  • Hib-conjugate vaccine


Want to know more? Contact us at

Webinar 20200422

Webinar 'In search of a corona vaccine'

On 22 April 2020, Intravacc's CSO Gideon Kersten gave a webinar (in Dutch) on the development of a vaccine against COVID-19, in conjunction with the Royal Netherlands Chemical Society. 

Read More Close

On Wednesday 22 April 2020, Intravacc, in conjunction with the Royal Netherlands Chemical Society, held a webinar 'In search of a corona vaccine'. In the webinar, Intravacc CSO Prof. dr. Gideon Kersten described what this search involves.

The webinar was held in Dutch, the slides shown are in English. 

You can view the webinar by clicking on the picture below.

About Intravacc

Intravacc is an experienced R&D organization with a proven track record in vaccinology of over 100 years. We have a wide range of expertise to independently develop vaccines from lead concept to clinical phase I/II studies as wel as our own product pipeline and patents.     

Read More Close
  • a wide range of science-based, one-stop-shop solutions
  • state-of-the-art facilities on site
  • Bacterial and Viral vaccines
  • OMV technology
  • Vero cell platforms
  • Innovative vaccine design
  • 3R research

Check out our factsheet on Intravacc 

Want to know more? Contact us at:







FActsheet vaccine



Intravacc to develop emergency and conventional COVID-19 vaccines

News | 14-05-2020

Intravacc today announced the development of three COVID-19 vaccine concepts. These concepts are all based on Intravacc’s platform technologies, that have been proven safe in humans.

Bilthoven, The Netherlands – 08.00 CET, May 14, 2020 - Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines, today announced the development of three COVID-19 vaccine concepts. These concepts are all based on Intravacc’s platform technologies, that have been proven safe in humans.

“This global COVID19 pandemic requires an international effort to understand the complexity of the disease and to develop innovative COVID-19 emergency and conventional vaccines”, said Dr. Jan Groen CEO of Intravacc. “We also need to establish partnerships with pharma for large scale manufacturing and global distribution of these vaccines”.

To develop safe and effective COVID-19 vaccines, Intravacc is focusing on emergency and conventional vaccines. Intravacc’s emergency vaccine is designed to activate T-cell responses. This emergency vaccine would reduce mortality and morbidity and as a result reduces the pressure on the public health system. For this vaccine Intravacc uses its outer membrane vesicle (OMV) technology.

For its conventional COVID-19 vaccine Intravacc will use OMV’s as a carrier for spike proteins of the virus to induce a protective antibody response. For the third concept Intravacc’s approved Vero cell platform will be used to develop an intranasal vector vaccine based on Newcastle disease virus, that can replicate in humans but does not cause disease.

The expected development timelines for these COVID-19 vaccines to enter into phase 1 range from 9 to 21 months.


About OMV platform technology

Gram-negative bacteria naturally release vesicles from their outer membrane. Outer membrane vesicles (OMVs) harbor bacterial proteins that play a role in establishing infection and survival of the bacterium within the human host. They are very suitable vaccine candidates. Genetic engineering techniques are being used to achieve the required antigenic composition, and to optimize immune modulating properties and safety. OMV’s are safe in humans and can be injected or administered needle free via the oral or intranasal route to achieve mucosal immunity. Intravacc’s OMV platform is fully scalable and allows for fast and efficient modification of antigen composition, either via genetic modification of the bacterial host or by conjugating antigens to stockpiled carrier OMVs.


About the Vero cell platform

Intravacc’s viral vaccine production processes is based on a cGMP-grade, regulatory approved, Vero cell line. This platform is being used for routine large-scale commercial vaccine manufacturing by clients world-wide. In addition, virus seed lots and clinical batches have regularly been produced on the Vero cells, for example Poliovirus, Enterovirus (EV71), and Respiratory Syncytial Virus (RSV).


About Intravacc

Intravacc is one of the leading institutes for translational vaccinology. As an established R&D organization with over 100 years’ experience in the development and optimization of vaccines and vaccine technologies, Intravacc has transferred its technology all over the world. Its track record includes technology transfer of oral polio, measles, DPT, Hib and influenza vaccines. The institute has state-of-the-art research and production (GMP) facilities; its aim is to substantially reduce development risks and costs of new vaccines in order to contribute to global health and equity in access to vaccines worldwide.




For more information, contact or check our website at

Intravacc ontwikkelt drie coronavaccins: een noodvaccin en twee conventionele vaccins

News | 14-05-2020

Intravacc werkt aan de ontwikkeling van drie coronavaccins: een noodvaccin en twee conventionele vaccins. Deze vaccins zijn gebaseerd op Intravacc’s technologieën, die bewezen veilig zijn in de mens.

Bilthoven, 14 mei 2020, 13.30 CETIntravacc, een vooraanstaand onderzoeksinstituut dat vaccins ontwikkelt en verbetert, werkt aan de ontwikkeling van drie coronavaccins: een noodvaccin en twee conventionele vaccins. Deze vaccins zijn gebaseerd op Intravacc’s technologieën, die bewezen veilig zijn in de mens.

“Deze mondiale COVID-19 pandemie vereist een internationale inspanning om de complexiteit van de ziekte te begrijpen en om innovatieve vaccins te ontwikkelen”, aldus Dr. Jan Groen, CEO van Intravacc. “We moeten ook samenwerken met farmaceutische bedrijven om te zorgen voor grootschalige productie en mondiale distributie van deze vaccins”.

Om veilige en effectieve vaccins tegen COVID-19 te ontwikkelen richt Intravacc zich op zowel noodvaccins als conventionele vaccins. Het noodvaccin van Intravacc is bedoeld om T-celreacties op te roepen. Het vaccin is vooral bedoeld om sterfte- en ziektecijfers te reduceren en zo de druk op de gezondheidszorg te verminderen. Voor dit vaccin gebruikt Intravacc zijn technologie rond buitenmembraanblaasjes (outer membrane vesicles, of OMV’s).

Voor zijn conventionele coronavaccin maakt Intravacc gebruik van de OMV’s als drager voor de S-eiwitten (of spike-eiwitten) van het virus om een beschermende antilichaamreactie in gevaccineerden te veroorzaken. Voor het derde concept gebruiken de onderzoekers Intravacc’s goedgekeurde Verocellplatform om een intranasaal vaccin te ontwikkelen. Dit gebeurt door deze technologie te combineren met het virus van de ziekte van Newcastle, een dierlijk virus dat zich in mensen kan repliceren maar in hen geen ziekte veroorzaakt.

Naar verwachting zal het tussen de 9 en 21 maanden duren voordat deze COVID-19 vaccins klaar zijn voor de eerste klinische testen.



Over OMV platformtechnologie

Gramnegatieve bacteriën scheiden van nature blaasjes van hun buitenmembraan uit. Deze buitenmembraanblaasjes (outer membrane vesicles of OMV’s) bevatten eiwitten die een rol spelen bij de infectie en bij het overleven van de bacterie in de gastheer. Ze zijn ook zeer geschikt voor gebruik als een vaccin. Via genetische manipulatie wordt de juiste samenstelling van antigenen verkregen, en worden zowel de immunologische modulerende eigenschappen en de veiligheid van het vaccin geoptimaliseerd. OMV’s zijn veilig in mensen en kunnen geïnjecteerd worden, of oraal en intranasaal toegediend worden om mucosale immuniteit op te wekken. Het OMV platform van Intravacc is volledig schaalbaar en kan op een snelle en efficiënte manier gecombineerd worden met verschillende antigenen, via modificatie van de bacterie zelf of via overdracht van antigenen aan de al geproduceerde OMVs.


Over Verocelltechnologie

Intravacc’s productieproces van virale vaccins is gebaseerd op een wettelijk goedgekeurde Verocell-lijn van cGMP kwaliteit. Dit platform wordt door klanten wereldwijd gebruikt voor reguliere grootschalige commerciële vaccinproductie. Daarnaast worden er regelmatig monsters en klinische batches op deze Verocel-lijn geproduceerd, o.a. voor Poliovirus, Enterovirus (EV71) en Respiratoir syncytieel virus (RSV).


Over Intravacc

Intravacc is een van de toonaangevende instituten op het gebied van translationele vaccinologie. Als onderzoeksorganisatie kan het bogen op meer dan honderd jaar ervaring in de ontwikkeling en verbetering van vaccins en vaccintechnologieën. Intravacc heeft zijn kennis van vaccins over de hele wereld overgebracht, o.a over polio, mazelen, DPT, Hib en influenzavaccins. Het instituut beschikt over state-of-the-art onderzoeks- en productie-(GMP) faciliteiten. De missie van Intravacc is het reduceren van de ontwikkelrisico’s en

-kosten van nieuwe vaccins om zo bij te dragen aan gezondheid en gelijke toegang tot vaccins wereldwijd.



Voor meer informatie, neem contact op met of kijk op

Webinar door CSO Intravacc: De zoektocht naar een coronavaccin

News | 21-04-2020

Op woensdag 22 april 2020 om 15.00 uur presenteert Intravacc samen met KNCV het webinar: ‘De zoektocht naar een coronavaccin’ door  Gideon Kersten, Chief Scientific Officer bij Intravacc.

Woensdag 22 april: 15.00 – 15.30 uur Webinar: De zoektocht naar een coronavaccin Met Prof Dr. Gideon Kersten, Chief Scientific Officer bij Intravacc

Deelname via Zoom en YouTube, kies het platform dat bij jou past.

Op woensdag 22 april om 15.00 uur presenteert Intravacc samen met KNCV (Kninklijke Nederlandse Chemische Vereniging) het webinar: ‘De zoektocht naar een coronavaccin’. Prof. Dr. Gideon Kersten, Chief Scientific Officer bij Intravacc, schetst in een half uur wat er komt kijken bij die zoektocht waar wereldwijd ruim zestig bedrijven en onderzoeksinstituten in een race tegen de klok in verwikkeld zijn.

Intravacc werkt samen met bedrijven en universiteiten bij de ontwikkeling van vaccins tegen infectieziekten, waaronder COVID-19. Intravacc vormt daarbij de schakel tussen het eerste vaccinconcept en de grootschalige productie ervan.

Voor de eerste en de goedkoopste leverancier van een coronavaccin ligt voor lange tijd een gegarandeerde wereldmarkt open. Maar wat komt er allemaal kijken bij het ontwikkelen van zo’n vaccin? Prof. Dr. Gideon Kersten, Chief Scientific Officer bij Intravacc, vertelt in het webinar in ca. 30 minuten hoe het proces van vaccinontwikkeling eruit ziet. Het webinar is interactief, dus deelnemers kunnen na afloop van zijn verhaal meteen hun vragen aan hem stellen.

Vanwege grote belangstelling is deelnemen via Zoom momenteel niet meer mogelijk. Heb je je al via Zoom geregistreerd? Zorg dan dat je je woensdag op tijd aanmeldt.

Via de livestream op het KNCV YouTube-kanaal bieden wij dezelfde mogelijkheden als via Zoom. Volg het webinar en stel jouw vragen, zodra de uitzending start. Deze link wordt zichtbaar vanaf 14.50 uur op ons KNCV YouTube-kanaal. Deelnemen is gratis! De presentatie zal in het Nederlands gehouden worden.

Over de spreker Gideon Kersten is Chief Scientific Officer bij Intravacc en bijzonder hoogleraar Vaccinontwikkeling aan de Universiteit van Leiden.

Intravacc appoints Dr Jan Groen as CEO

News | 03-04-2020

Intravacc today announced the appointment of Dr. Jan Groen as its Chief Executive Officer, effective 1 May 2020.


Bilthoven, The Netherlands – 07.00 CET, April 3, 2020 -

Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record developing viral and bacterial vaccines from discovery to lead concept to clinical phase I/II, today announced the appointment of Dr. Jan Groen as its Chief Executive Officer, effective 1 May 2020.


Dr Groen has many years of experience in Life Sciences and Biotech and holds a PhD degree in medical microbiology. Dr. Groen has held numerous executive management and board mandates in international profit and nonprofit companies and organizations. He built several successful commercial biotech companies in Europe and the US, and raised over $150 million for private and public companies.


Mr Nico Oudendijk, General Director of Intravacc said: “With Dr. Groen, we have found the right person to take Intravacc into the new phase of an independent vaccine research organization”.


Dr Groen stated: “I am delighted to join Intravacc, an institute with a tremendous track record in vaccinology. Developing and improving vaccines remains vitally important in the world today and with its unique one-stop facilities, Intravacc can be at the forefront of the (co)development of a coronavirus vaccine. I look forward to working together with the professional and highly committed staff to develop Intravacc into a successful organistation within the vaccine industry”.


About Intravacc

Intravacc is one of the leading institutes for translational vaccinology. As an established R&D organization with over 100 years’ experience in the development and optimization of vaccines and vaccine technologies. Intravacc has transferred its technology all over the world. Its track record includes technology transfer of oral polio, measles, DPT, Hib and influenza vaccines. The institute has state-of-the-art research and production (GMP) facilities; its aim is to substantially reduce development risks and costs of new vaccines in order to contribute to global health and equity in access to vaccines worldwide. For more information please visit



For more information, contact Mirjam Hartman, press officer: tel +31 6 11596994;


Intravacc announces the establishment of ‘Intravacc B.V.’, preparing for its privatization

News | 01-02-2019

Intravacc today announced the establishment of Intravacc B.V. This is an important step in the anticipated privatization of Intravacc and the sale of its activities to a private party.

In May 2018, the Dutch Ministry of Health, Welfare and Sport announced the start of the privatization process of the activities of Intravacc a leading organisation in the field of vaccines research & development. As the privatization is progressing, the buyer of Intravacc is expected to be announced in the second quarter of 2019.

Preparing for the privatization, Intravacc B.V., a private company with limited liability, was established today. Once the shares of Intravacc are sold to the selected buyer, Intravacc B.V. will become operational and all assets, staff, intellectual property and contracts & agreements will be transferred to the new entity. This ensures a smooth transition of the business and the knowledge base of Intravacc with no interruption in servicing current customers.

Intravacc and CDBIO sign a research and license agreement to further develop and commercialize a Meningococcal B vaccine

News | 28-12-2018

Intravacc and CDBIO today announced that they have signed a research and license agreement to further develop a vaccine against Meningococcal type B based on Intravacc’s proprietary Nonamen® vaccine technology.

Both parties will collaborate to tailor the Nonamen® concept for the Chinese market. Following the successful completion of this phase, CDBIO will receive a license to further develop and commercialize the vaccine.

Intravacc’s unique Nonamen® technology offers a broad panel of PorA proteins inserted in so called Outer membrane vesicles (OMV) expected to induce protection against the Meningococcal B (MenB) disease. Furthermore, the Nonamen® technology can be included in a Meningitis combination vaccine.

Under the agreement, both parties will collaborate to establish the development of an efficacious vaccine against prevalent Men B serotypes in China.

“We are very happy to partner with CDBIO and to be able to expand the global reach of our Nonamen technology. We trust this will help to prevent the occurrence of Men B in China considerably”, said Mr Nico Oudendijk, General Director of Intravacc.



Would you like to join our team?


VP Business Development (INT124)

Close Binnen Intravacc hebben wij een uitdagende functie voor een

VP Business Development (INT124)

Intravacc is dé plek in Nederland met een breed toegankelijke en complete infrastructuur voor translationeel vaccinonderzoek en -ontwikkeling. Op het instituut worden goede ideeën uit de wetenschap verder geholpen op het pad naar vaccins die waardevol zijn voor zowel de volksgezondheid als het bedrijfsleven. Het instituut rekent zowel de (inter)nationale overheid als diverse big pharma bedrijven tot haar klanten. In het komend jaar zal het instituut worden verzelfstandigd tot een publiek-private onderneming.

VP Business Development (m/v)

Vacaturenummer: INT124



De Vice President Business Development (VP-BD) maakt deel uit van het management team van Intravacc en rapporteert aan de CEO. De VP-BD zorgt voor het onderhoud en de acquisitie van nieuwe externe profit- en non-profitprojecten. Klanten van Intravacc zijn vaccinproducenten, kleine biotech bedrijven, universiteiten en NGO’s zoals de Wereld Gezondheidsorganisatie en de Bill & Melinda Gates Foundation. Daarnaast is de VP-BD verantwoordelijk voor strategische marketing van Intravacc.    


Je bent verantwoordelijk voor het (commercieel) ontwikkelen van de internationale profit en non-profit markt, in lijn met de strategische, wetenschappelijke en commerciële behoefte van Intravacc door:

  • het acquireren, leggen en onderhouden van contacten met (nieuwe) opdrachtgevers voor nieuwe opdrachten;
  • het wereldwijd identificeren en analyseren van new business en samenwerkingsverbanden en - als het gaat om product- en procesontwikkeling, registratie en commercie - met industriële partners, instituten en NGO’s deze trends in zakelijke kansen ontwikkelen;
  • in samenspraak met het programmamanagement c.q. de bestaande organisatie aangaan van (nieuwe) zakelijke mogelijkheden, onderhandelingen en/of vaststellen van prioriteiten met externe partijen;
  • onderhandelen met de klant extern en het afstemmen intern van commerciële en strategische voorwaarden
  • het aanbieden van technologische kennis tijdens klantbezoeken en congressen.
  • Het zorgdragen voor het actueel houden van de projecten in het pijplijn-overzicht en van de klantgegevens.



  • Heeft commerciële/zakelijke en wetenschappelijke kennis en ervaring op het gebied van de biotechindustrie en bij voorkeur op het gebied van vaccinontwikkeling en het valoriseren van gegenereerde kennis.
  • Heeft ervaring met onderhandelen en het opstellen van contracten
  • Weet verbindingen te leggen tussen wetenschappelijk inhoudelijke en business gerelateerde zaken.
  • Is een netwerker; kan beïnvloeden, onderhandelen, adviseren (programmamanagers, MT), is pro-actief, oplossingsgericht en weet relatienetwerken te onderhouden
  • Beschikt over een verscheidenheid aan stijlen om te overtuigen of te onderhandelen.
  • Is een teamspeler; in staat om op diverse niveaus in de organisatie te communiceren.
  • Werkt nauwkeurig; heeft oog voor detail en kan prioriteren.
  • Is flexibel, beschikt over het vermogen om onder tijdsdruk of bij weerstand te opereren en weet diverse activiteiten en projecten parallel uit te voeren.
  • Is cijfermatig sterk onderlegd.
  • Is bereid om regelmatig te reizen



Het salaris is afhankelijk van opleiding en relevante werkervaring en is gebaseerd op een volledig dienstverband (36-urige werkweek), exclusief 8% vakantietoelage.



Informatie over de functie en over de selectieprocedure kan informatie worden ingewonnen bij Gideon Kersten (030-7920460) of email:




Ben jij op zoek naar een baan voor langere tijd? Wil jij in een bedrijf met 150 super leuke collega`s werken? Wil jij je ontwikkelen en onmisbaar maken binnen een wetenschappelijk bedrijf? Stuur je cv en brief dan naar en wie weet ben jij degene die wij zoeken.


Download de vacaturetekst (pdf)

Acquisitie n.a.v. deze vacature wordt niet op prijs gesteld


Internships at Intravacc


Internships at Intravacc

Would you like to contribute to developing safe and effective vaccines?

At Intravacc we often have possibilities for internships for relevant MBO-, HBO-, and WO students.


The practical work of vaccine development is divided in 4 departments. Are you looking for an interesting and challenging internship? Then check below to see what each department has to offer.


If you are interested please send an email to Human Resources:

Make sure your email includes the following information:

  • the department and expertise you are interested in
  • when and how long you want to have your internship
  • your CV

We will let you know if we have availability during the time requested.


Please note that you need to be vaccinated to access the laboratories. The necessary vaccinations will be provided by Intravacc free of charge.

Process Development Bacterial Vaccines (PDBV)

In this department we develop processes for the production of bacterial vaccines. Most bacterial vaccines developed by Intravacc are either outer membrane vesicles vaccines or conjugate vaccines against many different pathogenic microorganisms. During process development we focus on the cultivation of bacteria (upstream processing, USP) and the purification of the vaccine from the culture broth (downstream processing, DSP). Processes are developed and each unit operation is optimized.

To answer the research questions and to meet the deliverables you will, during your internship, work with shaker flasks and bioreactors (from 1L to 70L and multi reactor systems) for the USP. For the DSP you will work with centrifugation and filtration techniques, these include dead-end and tangential flow filtration as well as size exclusion chromatography.

For conjugation technologies you will purify polysaccharides and perform chemical reactions to conjugate these polysaccharides to carrier proteins. This work involves analytical equipment like HPLCs. The department has a state of the art laboratory well equipped for all the research performed.

We often have openings for internships in all expertises described above.





Exploratory and Clinical Research (ECR)

In this department, we design, generate and test concept vaccines. Expertise represented in the department include molecular biology, virology, bacteriology, immunology and regulatory and clinical affairs.

For vaccine design we investigate which antigens are suitable to include in a vaccine:

  • From the pathogen perspective we for example analyze which antigens are conserved and might induce protection against several pathogen strains.
  • From the host perspective, we investigate how we can induce an effective immune response while minimizing side effects.
  • Finally, we investigate which pathogen characteristics could help optimizing vaccine yield, such as the ability of a bacterial strain to produce outer membrane vesicles or for a virus to optimize growth in our vero production cells.

This information is combined to design new bacterial, viral or cellular strains using molecular biological techniques. Next, these strains are tested in production processes by the process development departments and within ECR we study the efficacy and safety of these vaccines both in vitro and in vivo, using an array of immunological techniques. Of note, we strive to design new in vitro techniques that can replace animal experiments as much as possible.

Throughout the whole vaccine chain it is important to monitor the feasibility of a concept vaccine from a technical and economical, but also from a regulatory and clinical point of view. Since the product is meant to be used in healthy people, there are many criteria to be met and it is crucial to substantiate which choices have been made and why.

At ECR we often have openings for internships related to strain design and immunology.

Process Development Viral Vaccines (PDVV)

This department designs, develops and improves processes for production of viral vaccines. Disciplines in the department are:

  • In silico: mechanistic and statistical modeling for process understanding and reduction of experimental effort.
  • Upstream processing: development of culture strategies at different scales (from milliliters to hundreds of liters) and operational modes (like batch, fed-batch or perfusion) using several cell lines to produce a number of viruses.
  • Bioreactor characterization: understanding the bioreactor mass and energy transfer mechanisms for effective scale up and/or scale down. Assessment of alternative culture systems; and implementation of measures for proper evaluation of bioreactor performance.
  • Downstream processing: design of processes for purification of the target vaccine. This can include testing and optimization of unit operations like filtration, centrifugation, chromatography or inactivation.
  • High-throughput process development: use of platform approaches for fast screening and automation of upstream and downstream processes

This means that a broad range of internships are possible in the PDVV department. Ranging from working with cell culture using bioreactors, focusing on purification technologies using Äkta systems and in depth mathematical calculations using specialized software, but also establishing routines for various analysis methods like virus titration and ELISA. The department uses state-of the art equipment in recently renovated laboratories at BSL2/ML-II/MI-III level.


Analysis, Delivery and Formulation (ADF)

This department focuses on the development of analytical tests, stable formulation and appropriate methods for administration of (new) vaccines. To facilitate efforts throughout Intravacc, ADF is structured in the following expertise groups:

  • Biomolecular Mass Spectrometry – Mass spectrometry is used to identify and quantify proteins and LPS in vaccines, demonstrate (chemical) modifications in proteins and determine B and T cell epitopes in antigens.
  • Analytical Biochemistry – A vast array of immunochemical and molecular biological methods are used to identify antigens and determine their concentrations and activity.
  • Biophysics & Chemistry – The latest chemical synthesis and structural analysis tools are used to create vaccine components and characterize their biophysical properties.
  • Delivery & Formulation – New vaccines are composed to yield stable products that can be appropriately administered. Formulation of vaccines are investigated as liquid formulations or as solid formulations (freeze-drying, spray drying). Vaccine administration routes such as intranasal, intradermal or oral administration routes are also explored.
  • Quality Control - Investigational vaccines for use in clinical trials undergo scrutiny of validated assays.

We often have interesting internship assignments for students.

Visiting address | Antonie van Leeuwenhoeklaan 9 | 3721 MA | Bilthoven | The Netherlands
Postal Address | P.O. Box 450 | 3720 AL | Bilthoven | The Netherlands
Back To Top